Princeton OncoTherapeutics develops and patents a naturally-derived pharmaceutical compound targeting NADPH for the treatment of basal cell carcinoma (BCC) and glioblastoma (GBM). This compound demonstrates significant cytotoxicity against cancer cell lines and is being advanced toward clinical trials for topical BCC application and potential GBM therapies. The company is pursuing repurposing approval pathways to expedite the evaluation of this novel oncotherapy.
Funding
Funding not disclosed
Founders
Product
Problem
Basal cell carcinoma (BCC) and glioblastoma (GBM) are significant oncological challenges, with current treatments often involving invasive procedures or limited efficacy. The rapid metabolism and reproduction of cancer cells, facilitated by upregulated NADPH, present a key target for therapeutic intervention.
Solution
Princeton OncoTherapeutics is developing a patented topical pharmaceutical compound that targets NADPH, a critical cofactor upregulated in cancer cells for metabolism and proliferation. This naturally-derived compound, standardized and purified through proprietary methods, has demonstrated significant in vitro cytotoxicity against glioblastoma cell lines (U251, SF-268) and a BCC cell line (TE 354.T). The compound's potential for topical application in BCC treatment is supported by a US method and systems patent, with international applications filed. For glioblastoma, Princeton OncoTherapeutics is exploring its use as an intra-tumoral treatment, a therapeutic dressing post-excision, an adjunct to reduce pharmaceutical resistance by inhibiting Type IV collagen adhesion, and as a sensitizer for radiation therapy. The company is actively pursuing an investigator-initiated clinical trial protocol for this compound.
Target Audience
The primary target audience includes oncologists, dermatologists, and researchers specializing in skin cancer and brain tumor therapeutics, as well as pharmaceutical companies seeking novel oncotherapy agents.
Features
- Topical pharmaceutical compound targeting NADPH, a key metabolic cofactor in cancer cells.
- Demonstrated in vitro cytotoxicity against glioblastoma cell lines (U251, SF-268) and BCC cell line (TE 354.T).
- Patented US method and systems patent for topical treatment of Basal Cell Carcinoma.
- Potential applications for Glioblastoma include intra-tumoral treatment, post-surgical cavity dressing, and adjunct therapy to enhance existing treatments.
- Compound has prior human use approval for topical application for non-BCC indications, potentially streamlining regulatory pathways.
- Investigational New Drug (IND) enabling studies are underway, with an Investigator Initiated Trial (IIT) protocol developed.